A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors



Status:Completed
Conditions:Lung Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Cancer, Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/9/2019
Start Date:January 2015
End Date:December 12, 2018

Use our guide to learn which trials are right for you!

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

This is a study to determine the clinical benefit (how well the drug works), safety, and
tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both
drugs target the immune system and may act to promote anti-cancer effects.

Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on
certain immune cells and may act to promote anti-tumor effects.

Nivolumab is a fully human monoclonal antibody that binds to a molecule called PD-1 on immune
cells and promotes anti-tumor effects.

Eligible patients that enroll in the dose escalation portion of the study will be assigned to
one of three dose levels of varlilumab in combination with 3 mg/kg of nivolumab. The first
phase of the study will test the safety profile of the combination and determine which dose
will be studied in Phase ll of the overall study.

During Phase ll, depending on cancer type, groups of patients will be enrolled and receive
varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg
every 4 weeks in combination with nivolumab at 240 mg.

All patients enrolled in the study will be closely monitored to determine if there is
response to the treatment as well as for any side effects that may occur.

Key Inclusion Criteria:

1. Histologically-diagnosed advanced (unresectable and/or metastatic) Non-small Cell Lung
Cancer (Phase l only), Melanoma (Phase l only), Colorectal, Head and Neck SCC
(squamous cell carcinoma), Ovarian Cancer, Glioblastoma or Renal Cell Carcinoma.

- 1a. Head and Neck

Stage III/IV squamous cell carcinoma; Tumor progression or recurrence within 6 months
of last dose of platinum therapy in the adjuvant, primary, recurrent or metastatic
setting (or within 9 months if the patient received > 1 platinum-based chemotherapy
regimen in the metastatic setting). Active brain metastases or leptomeningeal
metastases are excluded; nasopharyngeal cancer, confirmed recurrent or metastatic
carcinoma of the nasopharynx and salivary gland or non-squamous histologies are also
excluded.

- 1b. Ovarian

Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal
carcinoma requiring original or subsequent relapse histologic documentation. A
platinum-taxane based chemotherapy regimen as frontline therapy must have been
completed.

Any histologic diagnosis of borderline, low malignant potential epithelial carcinoma
are excluded.

- 1c. Colorectal Cancer -Enrollment Completed

Metastatic or recurrent; prior treatment progression during, after, or intolerant
following the last administration of approved standard therapies (required therapies
apply).

- 1d. Glioblastoma -Enrollment Completed

Have histologically confirmed World Health Organization Grade IV malignant glioma
(glioblastoma).

- Previous first line therapy with at least radiotherapy and temozolomide.

- Participants must have shown unequivocal evidence of tumor progression.

- More than one relapse, secondary glioblastoma and prior treatment with
bevacizumab are excluded.

An interval of at least 12 weeks from the completion of radiation therapy to start of
study treatment is required.

- 1e. Renal Cell Carcinoma

Have histologically confirmed diagnosis of predominant clear cell renal cell
carcinoma.

- Must have received 1 or 2 prior anti-angiogenic therapies.

- No more than 5 total previous regimens of systemic therapy, including cytokines
and cytotoxic chemotherapy.

- Disease progression during or after the last treatment regimen and within 6
months before study entry.

2. No more than 5 prior anticancer regimens for advanced (recurrent, locally advanced or
metastatic) disease except for patients with GBM which must have first recurrence of
GBM by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI).

3. Measurable (target) disease.

4. Life expectancy ≥ 12 weeks.

5. If of childbearing potential (male or female), agree to practice an effective form of
contraception during study treatment and for at least 23 weeks after for female and 31
weeks after for male following last treatment dose.

Key Exclusion Criteria:

1. History of severe hypersensitivity reactions to other monoclonal antibodies.

2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.

3. Receipt of anti-CTLA-4 or anti-CD27 antibody within 3 months prior to the planned
start of study treatment.

4. Use of any monoclonal based therapies within 2-4 weeks prior to the first dose of
study treatment.

5. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to
the planned start of study treatment.

6. BRAF/MEK inhibitors within 2 weeks prior to the first dose of study treatment.

7. Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or
radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of
study treatment.

8. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within
2 weeks prior to first dose of study treatment.

9. Other prior malignancy, except for adequately treated basal or squamous cell skin
cancer or in situ cancers; or any other cancer from which the patient has been
disease-free for at least 3 years.

10. Active, untreated central nervous system metastases.

11. Active autoimmune disease or a documented history of autoimmune disease

12. Active diverticulitis.

13. Interstitial lung disease that is symptomatic or may interfere with the detection or
management of suspected drug-related pulmonary toxicity.

14. Significant cardiovascular disease
We found this trial at
19
sites
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Margaret Callahan, MD, PhD
Phone: 646-888-3359
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Jessica Geiger, MD
Phone: 216-444-0888
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Principal Investigator: Amy Weise, DO
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
Principal Investigator: Alain Algazi, MD
Phone: 415-502-3081
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Principal Investigator: Antonio Jimeno, MD
Phone: 303-724-2478
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Osama Rahma, MD
Phone: 617-632-6954
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
3225 Gallows Road
Fairfax, Virginia 22031
Principal Investigator: Jeanny Aragon-Ching, MD
Phone: 202-741-2481
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Fort Wayne, Indiana 46805
Principal Investigator: Alexander Starodub, MD
Phone: 260-373-8180
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Steven McCune, MD
Phone: 770-281-5100
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Miami Beach, Florida 33140
Principal Investigator: Jose Lutzky, MD
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
New Haven, Connecticut 06519
Principal Investigator: Mario Sznol, MD
Phone: 203-737-5381
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Fabio Iwamoto, MD
Phone: 212-342-0571
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Daniel Cho, MD
Phone: 212-263-4431
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Branimir Sikic, MD
Phone: 650-725-6427
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Portland, Oregon 97213
Principal Investigator: Rachel Sanborn, MD
?
mi
from
Portland, OR
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Julie Bauman, MD
Phone: 505-272-5490
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
3700 O St NW
Washington, District of Columbia 20057
(202) 687-0100
Principal Investigator: Michael Pishvaian, MD
Georgetown University Georgetown University is one of the world's leading academic and research institutions, offering...
?
mi
from
Washington,
Click here to add this to my saved trials
Washington, District of Columbia 20037
Principal Investigator: Jianqing Lin, MD
Phone: 202-741-2981
?
mi
from
Washington,
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
Principal Investigator: Rhonda Bitting, MD
Phone: 336-716-0327
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials